
Hyderabad based generic pharmaceutical company Hetero Labs is working on a “war footing” to make remdesivir available for Covid-19 patients in India, having entered into a licensing agreement with US-based Gilead Sciences to manufacture and market the antiviral drug in 127 countries, Hetero Labs’ managing director Vamsi Krishna Bandi told ET’s Teena Thacker in an interview.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3bq9MUJ
via
IFTTT
0 comments:
Post a Comment